

More information on the trials listed here is available at PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at www.cancer.gov/clinical_trials. A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.

Phase I

Safety, Pharmacokinetic, and Pharmacodynamic Study of KW-0761 in CC Chemokine-Receptor 4 Expressing Peripheral T-cell Lymphoma
NCT00355472, 0761-0501

Open-Label Single-Dose Study of Humanized MIK-BETA-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R Beta Subunit (CD122) in T-cell Large Granular Lymphocytic Leukemia
NCT00079196, CDR0000355111, NCI-04-C-0089

Study of Siplizumab (MEDI-507) in Patients With CD2-Positive Lymphoproliferative Disorders
NCT00075361, CDR0000344422, NCI-04-C-0031, MED-IMMUNE-MI-CP094

Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
NCT00105313, MI-CP107

Pilot Study of Alemtuzumab and Etoposide, Vincristine, Doxorubicin, Cyclophosphamide, and Prednisone (EPOCH) in Patients With Chemotherapy-Naïve CD52-Expressing Aggressive T- or NK-cell Lymphoma
NCT00069238, NCI-03-C-0304

Study of CHOP + Campath for T-cell, Null Cell, or Natural Killer (NK)-cell Lymphoma
NCT00161590, 0204-157

Phase I/II

Study of Yttrium Y 90 Labeled Humanized Anti-Tac Monoclonal Antibody and Pentetic Acid Calcium in Patients With Tac Expressing Hematologic Malignancies Other Than Adult T-cell Leukemia
NCT00019305, CDR0000065530, NCI-97-C-0110Q

Study of Clofarabine in Patients With Relapsed or Refractory T-cell or B-cell Aggressive Non-Hodgkin's Lymphoma
NCT00305721, OSSC-0408, WIRB-20050514

Study of Alemtuzumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (CHOP) Chemotherapy in Patients With Newly Diagnosed, Stage II-IV Aggressive Peripheral T-cell Non-Hodgkin's Lymphoma
NCT00363090, TSRCC-164-2006

Study of Bortezomib and CHOP in Patients With Advanced Stage Aggressive T-cell or Natural Killer (NK)/T-cell Lymphomas
NCT00374699, SMC IRB2005-07-021

Study of Clofarabine in Patients With Relapsed or Refractory T-cell or Natural Killer-cell Lymphoma
NCT00416351, MSKCC-06065

Phase II

Study of Daclizumab in Patients With Tac-Expressing HTLV-I-Associated Adult T-cell Leukemia/Lymphoma
NCT000019, NCI-00-C-0030J

Study of LMB-2 Immunotoxin in Patients With CD25-Positive Cutaneous T-cell Lymphoma
NCT00085085, CDR0000367248, NCI-04-C-0142, NCI-5943

Study of Initial Treatment With Methotrexate in Large Granular Lymphocytic (LGL) Leukemia
NCT00003910, CDR0000067089, ECOG-5998

Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-cell Leukemia
NCT00064155, CDR0000309057, NCI-03-C-0194, NCI-4553

Study of Alemtuzumab in Patients With HTLV-1-Associated Adult T-cell Leukemia/Lymphoma
NCT00061048, NCI-03-C-0194, NCI-4553

Pilot Study of Alemtuzumab in Patients With T-cell

Large Granular Lymphocyte Leukemia

NCT00345345, NHLBI-06-H-0190

Study of First-Line Therapy Comprising Methotrexate and Second-Line Therapy Comprising Fludarabine in Patients With T-cell Large Granular Lymphocytic Leukemia

NCT00278265, CDR0000454596, GCLLSG-LGL1, EU-20564

Study of Cyclosporine in Patients With T-cell Large Granular Lymphocyte Leukemia

NCT00363779, NCI-06-C-0177, NCI-P6830

Study of UCN-01 in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell or Mature T-cell Lymphomas

NCT00082017, NCI-04-C-0173, NCI-6070

Study of Forodesine in Patients With Recurrent or Refractory Advanced T-cell Leukemia

NCT00095381, BIOCRYST-BCX1777-T-04-201, UCLA-0404017-01

Study of Denileukin Diftitox in Patients With Tac-Expressing HTLV-1-Associated Adult T-cell Leukemia/Lymphoma

NCT00117845, NCI-05-C-0185, NCI-P6591

Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma

NCT00136565, LNH05-1T, Eudract: 2005-001563-66, Janssen: i061-341

Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-cell Lymphoma

NCT00211185

Study of the Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-cell Lymphoma

NCT00290433, ID03-0004

Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

NCT00364923, PDX-008, PROPEL

No Phase Specified

LAMPP Trial for Peripheral and Cutaneous T-cell Lymphoma

NCT00161239, CINJ#010410

Additional trials, listed below, are being conducted at Moffitt Cancer Center. For more information about these trials, please contact Gayle Behrle at (813) 745-6841 or e-mail: gayle.behrle@moffitt.org.

Phase I

Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Protocol #: 14123

Phase II

Study of R115777 in Large Granular Lymphocyte (LGL) Leukemia

Protocol #: 14774

Open-Label, Dose Escalation, Followed by Double-Blind, Randomized, Two-Dose, Parallel Group, Multi-Center Clinical Trial of Hu-Max-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Mycosis Fungoides Type CTCL (Stage IB-IVB) Who Are Refractory or Intolerant to Targretin (Bexarotene) and One Other Standard Therapy

Protocol #: 14742